RA
XERS icon

Royce & Associates’s Xeris Biopharma Holdings XERS Stock Holding History

Royce & Associates’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.65M Buy
461,153
+205,066
+80% +$1.31M 0.03% 544
2026
Q1 		$1.49M Buy
+256,087
New +$1.7M 0.01% 620

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Royce & Associates's XERS Position: Q2 2026 in Review

Royce & Associates increased its Xeris Biopharma Holdings (XERS) stake by 80% in Q2 2026, buying an estimated $1.31M and bringing the position to 461,153 shares worth $3.65M. The position accounts for 0.03% of the portfolio, ranked #544.

Royce & Associates first reported a position in XERS in Q1 2026 and has held it in 2 quarters since. 239 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Royce & Associates held 461,153 shares of Xeris Biopharma Holdings worth $3.65M as of Q2 2026.
  • Royce & Associates bought 205,066 Xeris Biopharma Holdings shares in Q2 2026, an estimated $1.31M.
  • Xeris Biopharma Holdings made up 0.03% of Royce & Associates's portfolio in Q2 2026, its #544 holding.
  • Royce & Associates first reported a position in Xeris Biopharma Holdings in Q1 2026 and has held it in 2 quarters since.
  • 239 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.